Biolattice

Executive Summary

Biolattice is a London-based private biotechnology company founded in 2020 that leverages AI-driven 3D biofabrication to advance regenerative medicine. Its proprietary BioLoom and Loominus platforms combine machine learning with advanced manufacturing to create complex tissue scaffolds and drug delivery systems. The company sits at the intersection of AI, drug delivery, and proteomics, targeting high-value applications in tissue engineering and personalized therapeutics. Although early-stage with no disclosed funding or revenue, Biolattice's focus on scalable, AI-optimized fabrication positions it to address critical bottlenecks in translating regenerative therapies to the clinic. The company has the potential to disrupt traditional scaffold manufacturing by enabling rapid prototyping and material optimization through computational design, reducing development timelines and costs. However, its lack of published validation or partnerships underscores significant technological and commercial risk.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement50% success
• Q4 2026Strategic Partnership with a Major Pharma or Medtech Company30% success
• Q2 2026Preclinical Proof-of-Concept Data Publication40% success